Literature DB >> 8678609

Chemoembolization for hepatocellular carcinoma. What, when, and for whom?

T Lehnert, C Herfarth.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8678609      PMCID： PMC1235239          DOI： 10.1097/00000658-199607000-00001

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  11 in total

1.  Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial.

Authors:  D Y Lin; Y F Liaw; T Y Lee; C M Lai
Journal:  Gastroenterology       Date:  1988-02       Impact factor: 22.682

2.  Results of treatment of patients with hepatocellular carcinoma with severe cirrhosis of the liver.

Authors:  N Fujio; K Sakai; H Kinoshita; K Hirohashi; S Kubo; R Iwasa; K C Lee
Journal:  World J Surg       Date:  1989 Mar-Apr       Impact factor: 3.352

Review 3.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Recovery of malignant tumor cells from the right atrium during hepatic resection for hepatocellular carcinoma.

Authors:  J Koo; K Fung; K F Siu; N W Lee; Z Lett; J Ho; J Wong; G B Ong
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860

5.  A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  G Pelletier; A Roche; O Ink; M L Anciaux; S Derhy; P Rougier; C Lenoir; P Attali; J P Etienne
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

6.  Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.

Authors:  K Takenaka; K Yoshida; T Nishizaki; D Korenaga; K Hiroshige; T Ikeda; K Sugimachi
Journal:  Am J Surg       Date:  1995-04       Impact factor: 2.565

7.  Primary treatment of hepatocellular carcinoma by arterial chemoembolization.

Authors:  H Bismuth; M Morino; D Sherlock; D Castaing; C Miglietta; P Cauquil; A Roche
Journal:  Am J Surg       Date:  1992-04       Impact factor: 2.565

8.  Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal.

Authors:  C C Wu; Y Z Ho; W L Ho; T C Wu; T J Liu; F K P'eng
Journal:  Br J Surg       Date:  1995-01       Impact factor: 6.939

9.  Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.

Authors:  M V Madden; J E Krige; S Bailey; S J Beningfield; C Geddes; I D Werner; J Terblanche
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

10.  Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.

Authors:  J L Raoul; D Guyader; J F Bretagne; R Duvauferrier; P Bourguet; D Bekhechi; Y M Deugnier; M Gosselin
Journal:  J Nucl Med       Date:  1994-11       Impact factor: 10.057
View more
  2 in total

1.  Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma.

Authors:  Kavous Firouznia; Hossein Ghanaati; Seyed Moayed Alavian; Payam Azadeh; Mohsen Nasiri Toosi; Arya Haj Mirzaian; Safa Najafi; Madjid Shakiba; Amir Hossein Jalali
Journal:  Hepat Mon       Date:  2014-12-28       Impact factor: 0.660

2.  Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury?

Authors:  S J Wigmore; D N Redhead; B N J Thomson; E J Currie; R W Parks; K K Madhavan; O J Garden
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.